CTLA4 and hepatocellular carcinoma: ICIs targeting PD‐1, PD‐L1, and CTLA‐4 can relieve hepatitis virus‐induced inhibition of T‐cells, restoring their activation and cytotoxic function, and serving as a systemic treatment option for HCC alongside targeted therapies.